Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
11 Aug 2021
11 Aug 2021
Historique:
received:
29
04
2021
accepted:
20
07
2021
entrez:
12
8
2021
pubmed:
13
8
2021
medline:
13
8
2021
Statut:
aheadofprint
Résumé
Anti-IgLON5 disease is a recently described neurological disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are under-reported. Here we describe the frequency and types of movement disorders in a series of consecutive patients with this disease. In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by three experts in movement disorders. Seventy two patients were included. In 41 (57%) the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least one movement disorder with a median of three per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients, 72%), chorea (24, 33%), bradykinesia (20, 28%), dystonia (19, 26%), abnormal body postures or rigidity (18, 25%), and tremor (15, 21%). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients, 32%) including dystonia (13), myorhythmia (6), chorea (4) or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31(43%) of patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only seven (13%) cases. Movement disorders are a frequent and leading cause of initial neurological consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.
Identifiants
pubmed: 34380749
pii: WNL.0000000000012639
doi: 10.1212/WNL.0000000000012639
pmc: PMC8520389
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 American Academy of Neurology.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Ann Neurol. 2020 Nov;88(5):1023-1027
pubmed: 32740999
Neurology. 2017 May 2;88(18):1736-1743
pubmed: 28381508
J Alzheimers Dis. 2017;59(1):13-20
pubmed: 28550263
Brain. 2018 Jan 1;141(1):13-36
pubmed: 29053777
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Mov Disord. 2013 Apr;28(4):543-7
pubmed: 23400857
Neurology. 2018 Oct 23;91(17):e1659
pubmed: 30348862
Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e136
pubmed: 26236762
Front Neurol. 2019 Oct 02;10:1056
pubmed: 31632341
Neurol Neuroimmunol Neuroinflamm. 2019 May 21;6(4):e577
pubmed: 31355313
Mov Disord. 1995 Mar;10(2):195-200
pubmed: 7538627
Mov Disord. 2011 May;26(6):947-57
pubmed: 21626541
Neurol Neuroimmunol Neuroinflamm. 2019 Dec 11;7(2):
pubmed: 31826985
J Neurol. 2019 Apr;266(4):1031-1033
pubmed: 30737575
Mov Disord Clin Pract. 2018 Nov 08;5(6):653-656
pubmed: 30637290
Neurology. 2017 Oct 3;89(14):1471-1475
pubmed: 28878050
Arch Neurol. 2010 Sep;67(9):1109-15
pubmed: 20837856
J Neuroinflammation. 2016 Sep 01;13(1):226
pubmed: 27586161
Neurol Neuroimmunol Neuroinflamm. 2019 Aug 12;6(6):
pubmed: 31454761
Neurology. 2013 Mar 19;80(12):1133-44
pubmed: 23427325
Lancet Neurol. 2014 Jun;13(6):575-86
pubmed: 24703753
J Neurol. 2020 Nov;267(11):3169-3176
pubmed: 31119450
Front Neurol. 2018 May 17;9:329
pubmed: 29867738
Mov Disord Clin Pract. 2020 May 05;7(5):557-559
pubmed: 32626803
Neurology. 2004 Jul 13;63(1):66-72
pubmed: 15249612
Mov Disord Clin Pract. 2021 Feb 25;8(3):460-463
pubmed: 33816679
Neurol Neuroimmunol Neuroinflamm. 2015 Dec 10;3(1):e186
pubmed: 26767190
Curr Opin Neurol. 2019 Jun;32(3):493-499
pubmed: 30694925
Mov Disord. 2014 Dec;29(14):1758-66
pubmed: 25370486
Mov Disord Clin Pract. 2016 Jul 28;4(3):441-443
pubmed: 30838275
Neurol Neuroimmunol Neuroinflamm. 2017 Jul 18;4(5):e385
pubmed: 28761904
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
Mov Disord. 2015 Feb;30(2):171-9
pubmed: 25487777
Neurology. 2018 Jun 12;90(24):1113-1115
pubmed: 29769372
N Engl J Med. 2015 Jan 15;372(3):249-63
pubmed: 25587949
J Neurol Sci. 2018 Feb 15;385:175-184
pubmed: 29406902
Medicine (Baltimore). 2019 May;98(20):e15706
pubmed: 31096519
Eur J Neurol. 2021 Apr;28(4):1392-1395
pubmed: 33175431
J Neurol Neurosurg Psychiatry. 2017 May;88(5):412-417
pubmed: 27919056
J Neuromuscul Dis. 2017;4(4):337-339
pubmed: 29103046
Mov Disord Clin Pract. 2020 Sep 29;7(Suppl 3):S83-S84
pubmed: 33015232
Mov Disord. 2016 May;31(5):762-4
pubmed: 27030137
Neurology. 2018 Jul 24;91(4):180-182
pubmed: 29970401
Nat Rev Neurol. 2018 Mar;14(3):183-189
pubmed: 29377011
J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):724-726
pubmed: 30032119
Neurology. 2021 Jun 8;96(23):e2901-e2902
pubmed: 33361260
Lancet. 2015 Apr 18;385(9977):1590
pubmed: 25933285
J Neuroimmunol. 2016 Nov 15;300:9-10
pubmed: 27806876
J Neurol. 2011 Nov;258(11):2058-68
pubmed: 21559939